The use of hypomethylating agents in the treatment of hematologic malignancies
暂无分享,去创建一个
[1] J. Issa,et al. Phase II study of low‐dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia , 2007, Cancer.
[2] H. Kantarjian,et al. Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia , 2007, Cancer.
[3] J. Issa,et al. Decitabine--bedside to bench. , 2007, Critical reviews in oncology/hematology.
[4] J. Issa,et al. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome , 2007, Cancer.
[5] Kelly M. McGarvey,et al. The cancer epigenome--components and functional correlates. , 2006, Genes & development.
[6] Michael Rytting,et al. Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia. , 2006, Blood.
[7] R. Shadduck,et al. Treatment of acute myelogenous leukemia with outpatient azacitidine , 2006, Cancer.
[8] R. Larson,et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] B. Cheson,et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. , 2006, Blood.
[10] M. Grever,et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. , 2006, Cancer research.
[11] J. Issa,et al. DNA methylation changes after 5-aza-2'-deoxycytidine therapy in patients with leukemia. , 2006, Cancer research.
[12] John M Bennett,et al. Decitabine improves patient outcomes in myelodysplastic syndromes , 2006, Cancer.
[13] M. Lübbert,et al. Superiority of prolonged low‐dose azanucleoside administration? , 2006, Cancer.
[14] P. Pandolfi,et al. Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome , 2006, Leukemia.
[15] S. Gore. Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies , 2005, Nature Clinical Practice Oncology.
[16] J. Issa. Optimizing therapy with methylation inhibitors in myelodysplastic syndromes: dose, duration, and patient selection , 2005, Nature Clinical Practice Oncology.
[17] M. Lübbert,et al. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2′-deoxycytidine (decitabine) in 177 patients , 2005, Annals of Hematology.
[18] M. Lübbert,et al. Characterization of DNA demethylation effects induced by 5-Aza-2'-deoxycytidine in patients with myelodysplastic syndrome. , 2005, Cancer research.
[19] J. Issa,et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] R. Pazdur,et al. Approval Summary: Azacitidine for Treatment of Myelodysplastic Syndrome Subtypes , 2005, Clinical Cancer Research.
[21] Neerja Vajpayee,et al. Acute leukemia associated with valproic acid treatment: A novel mechanism for leukemogenesis? , 2004, American journal of hematology.
[22] M. Szyf,et al. DNA methylation and breast cancer. , 2004, Biochemical pharmacology.
[23] Peter W. Laird,et al. DNA Hypomethylation and Ovarian Cancer Biology , 2004, Cancer Research.
[24] Jorge Cortes,et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. , 2004, Blood.
[25] J. Issa,et al. Results of decitabine (5‐aza‐2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia , 2003, Cancer.
[26] M. Maio,et al. 5-Aza-2'-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach? , 2003, Blood.
[27] H. Kantarjian,et al. Long‐term follow‐up of a phase I study of high‐dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias , 2003, Cancer.
[28] R. Liang,et al. Hypermethylation of gene promoters in hematological neoplasia , 2002, Hematological oncology.
[29] Manel Esteller,et al. Hypermethylation-associated Inactivation of the Cellular Retinol-Binding-Protein 1 Gene in Human Cancer. , 2002, Cancer research.
[30] Peter A. Jones,et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2'-deoxycytidine (decitabine) treatment. , 2002, Blood.
[31] J. Raymond,et al. Treatment of myelodysplastic syndromes with 5-azacytidine. , 2002, Leukemia research.
[32] J. Holland,et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] J. Holland,et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] M. Maio,et al. Promoter Methylation Controls the Expression of MAGE2, 3 and 4 Genes in Human Cutaneous Melanoma , 2002, Journal of immunotherapy.
[35] M. Lübbert,et al. Cytogenetic responses in high‐risk myelodysplastic syndrome following low‐dose treatment with the DNA methylation inhibitor 5‐aza‐2′‐deoxycytidine , 2001, British journal of haematology.
[36] B. Cheson,et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. , 2000, Blood.
[37] G. Pfeifer. p53 mutational spectra and the role of methylated CpG sequences. , 2000, Mutation research.
[38] M. Lübbert,et al. Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] G Flandrin,et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[40] J. Herman,et al. p15(INK4B) CpG island methylation in primary acute leukemia is heterogeneous and suggests density as a critical factor for transcriptional silencing. , 1999, Blood.
[41] S. Baylin,et al. Hypomethylation of pericentromeric DNA in breast adenocarcinomas , 1998, International journal of cancer.
[42] T Hamblin,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.
[43] G. Schwartsmann,et al. Decitabine (5-Aza-2'-deoxycytidine; DAC) plus daunorubicin as a first line treatment in patients with acute myeloid leukemia: preliminary observations. , 1997, Leukemia.
[44] J. Krischer,et al. Therapy of refractory or recurrent childhood acute myeloid leukemia using amsacrine and etoposide with or without azacitidine: a Pediatric Oncology Group randomized phase II study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] P. Maslak,et al. Pilot study of 5‐azacytidine (5‐AZA) and carboplatin (CBDCA) in patients with relapsed/refractory leukemia , 1996, American journal of hematology.
[46] J. Bryant,et al. Mitoxantrone and 5‐azacytidine for refractory/relapsed ANLL or CML in blast crisis: A leukemia intergroup study , 1993, American journal of hematology.
[47] S. Monfardini,et al. 5-Aza-2'-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes. , 1993, Leukemia.
[48] C. Schiffer,et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. , 1993, Leukemia.
[49] F. Mandelli,et al. Pilot study of 5-aza-2'-deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results. , 1993, Leukemia.
[50] M. Oken,et al. Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogenous leukemia: a study of the Eastern Cooperative Oncology Group. , 1992, Leukemia.
[51] D. Richel,et al. The antileukaemic activity of 5-Aza-2 deoxycytidine (Aza-dC) in patients with relapsed and resistant leukaemia. , 1991, British Journal of Cancer.
[52] P. Ritch,et al. Evaluation of continuous infusion low‐dose 5‐azacytidine in the treatment of myelodysplastic syndromes , 1991, American journal of hematology.
[53] C. Schiffer,et al. Low dose 5-azacytidine is ineffective for remission induction in patients with acute myeloid leukemia. , 1990, Leukemia.
[54] S. Monfardini,et al. 5-Aza-2'-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly. , 1989, Bone marrow transplantation.
[55] A. Look,et al. Combined etoposide and 5-azacitidine in children and adolescents with refractory or relapsed acute nonlymphocytic leukemia: a Pediatric Oncology Group Study. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] G Flandrin,et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. , 1985, Annals of internal medicine.
[57] C. Schiffer,et al. Therapy for chronic myelogenous leukemia in blast crisis with etoposide and 5-azacitidine administered by continuous infusion: a Cancer and Leukemia group B Study. , 1985, Cancer treatment reports.
[58] C. Presant,et al. Sequentially administered 5-azacitidine and amsacrine in refractory adult acute leukemia: a phase I-II trial of the Southeastern Cancer Study Group. , 1985, Cancer treatment reports.
[59] J. Saiki,et al. Effect of schedule on activity and toxicity of 5‐azacytidine in acute leukemia: A southwest oncology group study , 1981, Cancer.
[60] D. Miller,et al. 5-Azacytidine (NSC 102816): a new drug for the treatment of myeloblastic leukemia. , 1976, Blood.
[61] E. Freireich,et al. Treatment of acute leukemia with 5-azacytidine (NSC-102816). , 1973, Cancer chemotherapy reports.
[62] J. Finklestein,et al. 5-Azacytidine: a new active agent for the treatment of acute leukemia. , 1973, Blood.
[63] J. Issa,et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. , 2007, Blood.
[64] I. Wong,et al. Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications. , 2000, Blood.
[65] P. Néve,et al. Continuous infusion of low-dose 5-Aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. , 1997, Leukemia.
[66] R. Willemze,et al. A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893). , 1997, Leukemia.
[67] E. Estey,et al. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia , 1997, Leukemia.
[68] P. Néve,et al. Continuous infusion of low-dose 5-Aza-2′-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome , 1997, Leukemia.
[69] D. Case. 5-azacytidine in refractory acute leukemia. , 1982, Oncology.